Contribution of platelets to PAI-1 concentration in plasma of patients with primary and secondary thrombocytosis

Gm, Patrassi; Sartori, Maria; Randi, Maria Luigia; Zerbinati, P.; Theodoridis, Panagiotis; Pontarollo, Sara; Danesin, Cristina; Girolami, Antonio

doi:10.1016/s0268-9499(97)80099-9

Cited by 1 publication

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, Pósán et al [23] reported that in ET, similarly to polycythemia, clot fibrinolysis is impaired and results from increased PAI-1. Activated platelets may be a source of PAI-1 [22].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, abundant platelet-derived protein, platelet factor 4 (PF4), favours formation of an extremely dense fibrin clot [20]. It is well established that plasminogen activator inhibitor 1 antigen (PAI-1), which in an active form in part released from alpha granules of platelets, is a major inhibitor of fibrinolysis and is associated with prolonged clot lysis, seen also in platelet-rich plasma clots in ET [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Altered plasma fibrin clot properties in essential thrombocythemia

et al. 2015

View full text Add to dashboard Cite

Patients with increased thromboembolic risk tend to form denser fibrin clots which are relatively resistant to lysis. We sought to investigate whether essential thrombocythemia (ET) is associated with altered fibrin clot properties in plasma. Ex vivo plasma fibrin clot permeability coefficient (Ks), turbidimetry and clot lysis time (CLT) were measured in 43 consecutive patients with ET (platelet count from 245 to 991 × 10(3)/µL) and 50 control subjects matched for age, sex and comorbidities. Fibrinolysis proteins and inhibitors together with platelet activation markers were determined. Reduced Ks (-38%, p < 0.0001) and prolonged CLT (+34%, p < 0.0001) were observed in ET. The differences remained significant after adjustment for fibrinogen and platelet count. ET was associated with a slightly shorter lag phase (-5%, p = 0.01) and higher maximum absorbency of the turbidimetric curve (+6%, p < 0.001). The ET patients had higher plasma P-selectin by 193% (p < 0.00001) and platelet factor 4 (PF4) by 173% (p < 0.00001), with higher P-selectin observed in 19 (44%) patients with JAK-2 gene V617F mutation. Higher t-PA (+20%, p < 0.001), 23% higher plasminogen activator inhibitor-1, PAI-1 (+23%, p < 0.01) and unaltered thrombin-activatable fibrinolysis inhibitor, plasminogen and α2-antiplasmin activity were found in the ET group. Ks inversely correlated with fibrinogen, PF4 and C-reactive protein. CLT positively correlated only with PAI-1. Patients with ET display prothrombotic plasma fibrin clot phenotype including impaired fibrinolysis, which represents a new prothrombotic mechanism in this disease.

show abstract

Section: Discussionmentioning

confidence: 99%